DGAP-News

Novavax Announces Proposed Public Offering of Common Stock - Seite 2

vaccine technology, the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.

Forward-Looking Statements

Statements contained in this release, including those relating to the sale of
common stock, and those statements using words such as 'expects' and 'intends'
are forward-looking statements that involve a number of risks and uncertainties
that could cause actual results to differ materially from those in the
forward-looking statements. These risks and uncertainties include, but are not
limited to: our ability to successfully complete the offering on terms and
conditions satisfactory to us; the possible adverse impact on the market price
of our shares of common stock due to the dilutive effect of the securities to
be sold in the offering; capital market risks; our ability to raise additional
capital when needed; and other risk factors identified from time to time in the
reports we file with Securities and Exchange Commission (SEC), including our
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports
on Form 8-K, which are available at www.sec.gov. We caution investors not to
place considerable reliance on the forward-looking statements contained in this
press release. The forward-looking statements in this press release speak only
as of the date of this document, and we undertake no obligation to update or
revise any of the statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors, potential
investors, and others should give careful consideration to these risks and
uncertainties.


CONTACT: Barclay Phillips
SVP, Chief Financial Officer and Treasurer
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

04.06.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language: English
Company: Novavax, Inc.


United States
ISIN: US6700021040


End of News DGAP News-Service
---------------------------------------------------------------------
272291 04.06.2014